Spectral Diagnostics, Toray Medical join forces to tackle sepsis:
This article was originally published in Clinica
Executive Summary
Canadian diagnostics developer Spectral Diagnostics and Toray Medical, a subsidiary of Japan's diversified chemicals group Toray, have formed what they claim to be the first "theranostic" alliance to improve management of severe sepsis. Under the agreement, the two companies will co-promote the use of Spectral's Endotoxin Activity Assay (EAA) for measuring levels of blood-borne endotoxin, together with Toray's Toraymyxin blood purification device for removing the noxious agent. Endotoxin is the most common mediator of sepsis and enables doctors to assess a patient's risk of developing the severe form of the condition.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.